The new reporting requirements were slated to start Jan. 1, but CMS is proposing a six-month delay. The requirements then would take effect July 1, 2022.
CMS said the delay will allow affected parties more time to make the “complex system changes necessary to implement the new best price” program and ensure the industry gets through the pandemic.
Drugmakers sued HHS over the CMS best price rule in the U.S. District Court for the District of Columbia last week.
CMS also proposed delaying the inclusion of some U.S. territories, including Guam, Puerto Rico and the Virgin Islands, in the Medicaid drug rebate program. The effective date for their inclusion was to be in April 2022, but CMS is proposing a two-year delay.
Read more here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.